New obesity drug VCT220 put through drug interaction tests
NCT ID NCT07065058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked how a new experimental drug for obesity, VCT220, interacts with three common medications (repaglinide for diabetes, rosuvastatin for cholesterol, and digoxin for heart conditions). Twenty-four healthy overweight adults took VCT220 alone and then with the other drugs to see if there were any safety concerns or changes in drug levels. The goal was to gather important safety and dosing information for future trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VCT220
What this could lead to
If successful, this study will show whether VCT220 can be safely combined with common medications, guiding future obesity treatments.
What could go wrong
This is an early Phase 1 trial with only 24 healthy people, so results may not apply to patients or predict real-world safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Second University Hospital
Chengdu, Sichuan, 610041, China